Fara Maristany-Braso
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.
Journal: Breast (Edinburgh, Scotland)
Published: January 12, 2026
Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].
Journal: ESMO open
Published: January 06, 2026
Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.
Journal: ESMO open
Published: December 17, 2025
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.
Journal: Breast cancer research and treatment
Published: November 04, 2025
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.
Journal: NPJ breast cancer
Published: September 15, 2025
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
Journal: NPJ precision oncology
Published: September 06, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 19, 2025
Case Report: Personalized management of HER2-positive breast cancer with advanced nodal disease during pregnancy: a clinical case and review.
Journal: Frontiers in oncology
Published: July 24, 2025
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 11, 2025
Last Updated: 09/26/2026